Research progress of adalimumab in pediatric Crohn 's disease / 国际儿科学杂志

ABSTRACT

Adalimumab is an anti-TNF-α recombinant IgG1, a fully humanized monoclonal antibody binding soluble human tumor necrosis factor alpha with high affinity and specificity. It has lower immunogenicity and can be used clinically for induction and maintenance of remission in Crohn' s disease. The effectiveness, sustainability and safety of adalimumab in the treatment of pediatric Crohn' s disease has been gradually con-firmed, which may pave the way for new therapy to treat children with refractory Crohn's disease.